A novel combination treatment for fragile X syndrome predicted using computational methods

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Fragile X syndrome (FXS) is a genetic neurodevelopmental disorder with diverse symptoms, including intellectual disabilities and behavioral challenges like autism spectrum disorder.
• Current therapeutic approaches for FXS are limited due to the syndrome's complexity and symptom heterogeneity.
• Existing research suggests potential therapeutic targets in GABA and cyclic adenosine monophosphate (cAMP) metabolism, pathways implicated in FXS pathophysiology.

Purpose of the Study:

• To identify a novel therapeutic strategy for Fragile X syndrome using a data-driven drug discovery platform.
• To investigate the potential of combining ibudilast and gaboxadol for treating the multifaceted symptoms of FXS.
• To evaluate the efficacy and safety of this combination therapy in a preclinical mouse model of FXS.

Main Methods:

• Utilized a data-driven drug discovery platform to identify potential therapeutic combinations.
• Administered ibudilast (a phosphodiesterase inhibitor) and gaboxadol (a GABA_A receptor agonist) individually and in combination to a Fragile X syndrome mouse model.
• Assessed cognitive function and behavioral phenotypes (hyperactivity, aggression, stereotypy, anxiety) in treated mice.

Main Results:

• Ibudilast monotherapy improved cognitive performance in FXS mice.
• Gaboxadol monotherapy ameliorated behavioral deficits including hyperactivity, aggression, stereotypy, and anxiety.
• Combination therapy with ibudilast and gaboxadol rescued both cognitive deficits and behavioral issues more effectively than monotherapies.
• The combination treatment demonstrated no evidence of tolerance or adverse effects upon chronic administration.

Conclusions:

• The combination of ibudilast and gaboxadol offers a promising therapeutic strategy for Fragile X syndrome by targeting multiple pathological pathways.
• This dual-drug approach effectively addresses a wider range of FXS symptoms compared to single-drug treatments.
• The findings suggest potential therapeutic applications for this combination therapy in FXS patients and possibly in idiopathic autism.